Unknown

Dataset Information

0

Targeting c-MET by Tivantinib through synergistic activation of JNK/c-jun pathway in cholangiocarcinoma.


ABSTRACT: Clinical treatment options for human cholangiocarcinoma (CC) are limited. c-MET, a high-affinity receptor for hepatocyte growth factor (HGF), is deregulated in many cancers. Its role in cholangiocarcinogenesis remains unclear. In current study, 23 corresponding tumor- and non-tumor tissues, taken from patients with intrahepatic (iCC) and perihilar cholangiocarcinoma (pCC), who underwent liver resection, were analyzed. The relationship of clinicopathological features and c-MET, as well as c-jun N-terminal kinase (JNK) was evaluated. The anti-tumor effects of Tivantinib, a small-molecule inhibitor with potent activity against the c-MET kinase, was investigated in three human CC cell lines, namely HUCC-T1, TFK-1, and EGI-1. In comparison with the results obtained in non-tumor tissue samples, c-MET was overexpressed in 91.3 % of tumor tissues (p?

SUBMITTER: Wei K 

PROVIDER: S-EPMC6408560 | biostudies-literature | 2019 Mar

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC4823078 | biostudies-literature
| S-EPMC11312940 | biostudies-literature
2024-11-26 | PXD058235 | Pride
| S-EPMC7199950 | biostudies-literature
| S-EPMC7801618 | biostudies-literature
| S-EPMC9546856 | biostudies-literature
| S-EPMC8315012 | biostudies-literature
| S-EPMC9572343 | biostudies-literature
| S-EPMC6736844 | biostudies-literature
| S-EPMC7996994 | biostudies-literature